ALNY News and Press, Alnylam Pharmaceuticals Inc. From 08/03/22

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are poised to post a new all-time high upon market open Wednesday. The RNA interference (RNAi) drug specialist's stock price rose by as much as 53% in premarket action this morning. What's fueling this supercharged move higher tod...

Gainers: Applied DNA Sciences ( APDN ) +93% . Alnylam Pharmaceuticals ALNY +55% . Poseida Therapeutics PSTX +47% . NeuroOne Medical Technologies ( NMTC ) +31% . Sonoma Pharmaceuticals ( SNOA ) +21% . Losers: BridgeBio Pharma B...

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) added nearly 42% in the morning hours Wednesday after the RNAi therapeutics company said that its Phase 3 trial for patisiran reached the primary goal in transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. According to ...

Alnylam Pharmaceuticals ( ALNY ) made headlines across the biotech space on Wednesday after the RNAi therapeutics company announced that its ATTR amyloidosis therapy patisiran met the main goal in a Phase 3 trial. The much-awaited data readout propelled Alnylam ( ALNY ...

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) added ~48% in the pre-market Wednesday after the RNAi therapeutics company said that its Phase 3 trial for patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy reached the main goal. The APOLLO-B trial inv...

– Patisiran Met the Primary Endpoint with a Statistically Significant Improvement in 6-Minute Walk Test Compared to Placebo at 12 Months – – Patisiran Also Met the First Secondary Endpoint with a Statistically Significant Improvement in Quality of Life, as...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has ranked #1 on Fast Company’s fourth annual list of Best Workplaces for Innovators . The 2022 Best Workplaces for Innovators ranks 100 winners f...

After earning its fifth new drug approval in four short years, you might expect Alnylam (NASDAQ: ALNY) to take a moment to rest on its laurels. Those of you who know the company a little better won't be surprised to learn that it just did the opposite. Instead of taking a break, the...

Shares of RNA interference concern Arrowhead Pharmaceuticals are down over 50% since making an all-time high in June 2021. The company’s approach has been validated by its four licensing deals, rival Alnylam’s commercial success, and Novo Nordisk’s buyout of RNAi ...

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Alnylam Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation